180 Life Sciences CORP 8-K filings

180 Life Sciences Corp. has entered into a Settlement and Mutual Release Agreement with Elray Resources, Inc. and Luxor Capital, LLC to repurchase 1,318,000 shares of its common stock, simplifying its capital structure.

180 Life Sciences Corp. resolves ongoing litigation with AmTrust International Underwriters DAC and AmTrust Financial Services, Inc. through a settlement involving a cash payment and issuance of common stock.

180 Life Sciences Corp. files an amendment to correct scrivener's errors in previous filings related to the conversion ratio and voting rights of the Series B Convertible Preferred Stock.

180 Life Sciences Corp. resolves legal actions with Dr. Marlene Krauss, former executive of KBL Merger Corp. IV, by issuing shares, making a cash payment, and securing a voting agreement.

180 Life Sciences Corp. appoints Eric R. Van Lent as Chief Accounting Officer, replacing Blair Jordan, and adjusts compensation for both the new CAO and the CEO, Blair Jordan.

180 Life Sciences Corp. amends its separation agreement with former CEO James N. Woody, appoints Ryan Smith as Lead Independent Director, and officially names Blair Jordan as CEO.

180 Life Sciences Corp. amended its 8-K filing to include details about the conversion of Series B Preferred Stock and the resulting changes in voting rights and control.

180 Life Sciences Corp. stockholders approved an amendment to the 2022 Omnibus Incentive Plan, increasing the share limit to 1,000,000, along with other key proposals at the 2024 Annual Meeting.

180 Life Sciences Corp. has priced a $2.9 million registered direct offering and concurrent private placement to fund working capital and general corporate purposes.

180 Life Sciences Corp. reports the immediate resignation of its Chief Financial Officer, Omar Jimenez, and the appointment of Interim CEO Blair Jordan as interim principal financial officer.

180 Life Sciences Corp. has regained compliance with Nasdaq listing rules after appointing a new independent director to its audit committee.

180 Life Sciences Corp. has appointed Stephen Shoemaker to its Board of Directors, replacing Omar Jimenez who resigned to focus on his CFO role, and the company has regained compliance with Nasdaq listing rules.

180 Life Sciences Corp. has appointed a Senior Technology Consultant and initiated the integration of its recently acquired Gaming Technology Platform.

180 Life Sciences Corp. has set December 27, 2024, as the date for its 2024 Annual Meeting of Shareholders.

180 Life Sciences Corp. has appointed Jay Goodman, a seasoned executive with experience in SaaS and iGaming, to its Board of Directors, effective October 24, 2024.

180 Life Sciences Corp. successfully completed a warrant exercise, receiving $3.3 million and issuing new warrants.

180 Life Sciences Corp. is issuing new warrants to incentivize the exercise of existing warrants, potentially raising approximately $3.3 million.

180 Life Sciences Corp. is expanding into the online gaming industry with a newly acquired blockchain-based gaming platform, targeting both B2C and B2B markets.

180 Life Sciences Corp. has regained compliance with Nasdaq's minimum stockholders' equity rule and is shifting its strategic focus to the global iGaming sector.

180 Life Sciences Corp. has acquired an online gaming technology platform, reported positive results from a CBD pill study, and improved its financial position by settling legacy liabilities.

180 Life Sciences Corp. has announced the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024, following the resignation of Ozan Pamir.

180 Life Sciences Corp. has reached a separation agreement with its former CEO, Sir Marc Feldmann, involving stock and option grants, and a mutual release of claims.

180 Life Sciences reports successful clinical trial results for a new solid CBD formulation showing enhanced oral uptake compared to a liquid formulation.

180 Life Sciences has been granted an extension until September 20, 2024, by Nasdaq to meet minimum stockholders' equity requirements for continued listing.

180 Life Sciences has received an extension from Nasdaq to meet minimum equity requirements for continued listing, with a deadline of July 31, 2024.

180 Life Sciences Corp. has appealed Nasdaq's delisting determination due to non-compliance with minimum stockholders' equity requirements, temporarily halting the delisting process.

180 Life Sciences Corp. received a delisting notice from Nasdaq after failing to meet the minimum stockholders' equity requirement and intends to appeal the decision.

180 Life Sciences Corp. has announced the departure of its CEO and Chief Scientific Officer, along with the appointment of an interim CEO and new consulting agreements.

180 Life Sciences Corp. has changed its independent auditor from Marcum LLP to M&K CPAs, PLLC and received a $1.5 million net payment from an insurance claim.

180 Life Sciences has regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive days.